

Meet The Professor: Optimizing the Management of Soft Tissue Sarcoma and Related Connective Tissue Disorders — Part 1 of a 2-Part Series

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Updated efficacy results from an integrated analysis of the cohort of patients with NTRK fusion-positive sarcomas who received entrectinib in the ALKA-372-001, STARTRK-1 and STARTRK-2 trials included which of the following observations?**
 - No responses were reported in patients with NTRK fusion-positive sarcomas
 - Responses were reported only in patients with NTRK fusion-positive chondrosarcoma
 - Responses were reported only in patients with NTRK fusion-positive gastrointestinal stromal tumors
 - Responses were reported in patients with a variety of NTRK fusion-positive sarcomas
- 2. Atezolizumab was approved for which of the following indications in patients with sarcomas?**
 - Unresectable or metastatic alveolar soft part sarcomas
 - Metastatic desmoid tumors
 - Metastatic or locally advanced epithelioid tumors
- 3. Which of the following drug types best describes the mechanism of action of nirogacestat?**
 - EZH2 inhibitor
 - Small-molecule gamma secretase inhibitor
 - KIT/PDGFR α inhibitor
- 4. The Phase III DeFi trial evaluating nirogacestat versus placebo for desmoid tumors demonstrated which of the following?**
 - A greater than 70% decrease in the risk of disease progression or death with nirogacestat
 - An approximate 30% decrease in the risk of disease progression or death with nirogacestat
 - A less than 10% decrease in the risk of disease progression or death with nirogacestat
- 5. Which of the following adverse events was observed only in patients with desmoid tumors who received nirogacestat in the DeFi trial and not in patients who received placebo?**
 - Hypophosphatemia
 - Ovarian dysfunction
 - Maculopapular rash